Engflag

Clofazimine

Quick links to important sections

Clofazimine

Clofazimine_PL

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clofazimine

Quick Facts

Property Description
Active Ingredient Clofazimine (B663)
Form Oral Capsule
Pharmacological Class Antimycobacterial Agent, Rimino-phenazine Antibiotic
General Purpose Treatment of chronic mycobacterial infections
Origin Synthetic Compound

Clofazimine: Definition and Pharmacological Classification

Clofazimine is a potent, synthetic compound classified as a specialized Antimycobacterial agent belonging to the Lipophilic Rimino-phenazine antibiotic class. This classification places it in a category specifically designed to combat the unique and persistent bacteria responsible for chronic infections. The active ingredient, Clofazimine, is a Phenazine derivative also known chemically as B663. Its role in global public health is reflected by its inclusion in the Model List of Essential Medicines.

Composition, Origin, and Pharmaceutical Form

The medication is a single active ingredient product primarily delivered as a soft gel capsule, which is the standardized dosage form for oral administration. Clofazimine is entirely synthetic. The agent is used in treating specific bacterial diseases and possesses distinct properties as an Iminophenazine dye. The active ingredient is highly lipophilic, and the formulation utilizes an oily vehicle inside the capsule to optimize drug absorption.

General Purpose and Dual-Action Benefit

The general therapeutic purpose of Clofazimine is to control and neutralize severe, long-term infections caused by mycobacteria in patient groups. The drug is characterized by a dual-action benefit: it functions primarily by killing bacteria by interfering with microbial DNA, coupled with an auxiliary Immunomodulatory effect. This anti-inflammatory property helps to moderate the body's excessive immune reaction, supporting the management of persistent infectious disease pathology.

Regulatory References

  1. Clofazimine (MeSH)
  2. WHO Essential Medicines List

What side effects are possible with Clofazimine?

Clofazimine: Possible Side Effects and Safety Information

Clofazimine's safety profile is officially characterized by specific, documented adverse reactions and safety limitations outlined in regulatory prescribing information.

Adverse Reaction Scope

The most distinctive and Very Common effect is skin and tissue discoloration, which results in a reddish-brown to black pigmentation of the skin, conjunctiva, cornea, and bodily fluids (e.g., urine, feces, sweat). This discoloration is dose-dependent and may take months or years to resolve after treatment cessation.

Common adverse reactions primarily involve Gastrointestinal Disorders, including abdominal pain, diarrhea, nausea, vomiting, and anorexia. Ichthyosis (dry, scaly skin) is also commonly documented among Skin and Subcutaneous Tissue Disorders.

System-Organ Class Key Adverse Reactions (Regulatory Listings)
Gastrointestinal Abdominal pain, Diarrhea, Nausea, Vomiting
Skin Pigmentation, Ichthyosis, Pruritus
Nervous System Dizziness, Headache, Drowsiness

Serious Adverse Reactions and Safety Constraints

The regulatory labels identify several serious adverse reactions. These include potentially life-threatening Gastrointestinal Obstruction and Enteropathy, which are specifically associated with long-term and high-dose use of the medicine. Other serious risks involve Gastrointestinal Bleeding, Hepatic Injury, and Jaundice.

Specific safety considerations exist for certain patient populations: the medicine should be used with caution or is contraindicated in individuals with severe hepatic or renal impairment. Furthermore, the skin pigmentation has been noted in official safety documents as potentially leading to secondary depression and suicide ideation, requiring attention. High-level warnings also address the risk of QT-interval prolongation (a cardiac safety risk) when co-administered with certain other drugs.

Overdose and Emergency Response

️ Clofazimine Overdose and When to Seek Help

Clofazimine overdose, while not always resulting in immediate acute toxicity, is primarily associated with an exaggeration of its known adverse effects and the potential for severe, long-term consequences. The drug is known to accumulate in various organs over time, which can contribute to chronic toxicity.

Overdose Symptoms

Symptoms of a potential overdose or acute toxicity, which may involve excessive chronic use, often center on the gastrointestinal tract and may include:

  • Severe Gastrointestinal Issues: Intense abdominal pain, nausea, vomiting, and diarrhea. In rare, severe cases, this may progress to bowel obstruction or gastrointestinal bleeding due to clofazimine crystal deposition in the intestinal lining, which may require surgical intervention.
  • Skin and Systemic Discoloration: A rapid or pronounced intensification of the characteristic orange-pink to brownish-black discoloration of the skin and body fluids (stools, urine, tears, sweat).
  • Cardiac Effects: Signs of an abnormal heart rhythm (QT prolongation), such as dizziness, fainting, or an unusually fast or pounding heartbeat.

When to Seek Immediate Medical Help

Call for emergency medical assistance or a poison control center immediately if you or someone else has taken more than the prescribed dose. Do not wait for symptoms to appear.

Seek urgent medical attention if you experience any of the following while on therapy:

  • Severe, sudden abdominal pain.
  • Black or bloody stools, or vomiting that looks like coffee grounds.
  • Symptoms of an irregular heartbeat (e.g., palpitations, lightheadedness).
  • Unusual weakness or yellowing of the skin or eyes (jaundice).

If severe gastrointestinal symptoms develop, the dose may need to be reduced or the drug discontinued under strict medical supervision.

Therapeutic Uses of Clofazimine

What Clofazimine Treats: Main Uses and Benefits

The primary role of clofazimine is in the management of persistent, severe mycobacterial infections. It is specifically used as part of combination therapy to manage lepromatous leprosy, including cases that are resistant to dapsone. This essential use plays a role in managing the causative organism and supports the maintenance of functional stability.

Clofazimine is a crucial agent used in combination therapy to combat the widespread and persistent forms of Hansen’s disease. It is applied across therapeutic domains involving chronic infection where the medicine is applied in addressing the underlying infection. Additionally, it contributes a relevant therapeutic benefit in addressing the severe, painful immunological complication known as Erythema Nodosum Leprosum (ENL), which presents with clusters of tender, red skin nodules and systemic symptoms like fever.

By providing anti-inflammatory support, the medication contributes to improved day-to-day comfort during acute episodes and may help reduce the risk of recurrent inflammation that disrupts functional stability. It is also used in certain cases of multidrug-resistant tuberculosis (MDR-TB) and Non-tuberculous Mycobacterial (NTM) diseases, offering the supportive therapeutic benefit needed to support the management of the underlying infection when facing challenging pathogen resistance.

Quick Fact: Therapeutic Use Profile
Primary Domain Management of Chronic Mycobacterial Infections
Symptom Type Symptoms related to inflammatory or irritative states (e.g., painful ENL nodules)
Use Context Applied in clinical settings that involve acute or unstable symptom patterns
Core Benefit Provides support that helps ease the overall symptom burden

Eligibility and Restrictions for Use

Official Eligibility Profile for Clofazimine Use

The eligibility to use clofazimine is strictly defined by regulatory authorities based on a patient's medical history, age, and physiological status.

Eligibility Status Official Regulatory Statement
Absolute Contraindication Use is contraindicated in patients with a known history of hypersensitivity to clofazimine or any of the product's excipients.
Established Use Use is established and formally indicated for adults as part of combination therapy for lepromatous leprosy.
Pediatric Restriction Safety and effectiveness have not been established in the pediatric patient population.
Hepatic/Renal Caution Use requires caution in patients with severe renal impairment. Use should be avoided in patients with severe hepatic impairment unless the clinical benefit clearly outweighs the risk.
Pregnancy Restriction Not recommended during pregnancy due to the potential for fetal harm; females of reproductive potential must have a negative pregnancy test and use effective contraception during and for four months after treatment.
Conditional Use Caution is required in patients with pre-existing gastrointestinal disease (due to accumulation risk) or known cardiac conditions that prolong the QT interval.

These official regulatory statements establish clear boundaries for the eligible population. The primary denial of eligibility is based on hypersensitivity, while use in children is not established. Eligibility for adults with organ impairment or those of reproductive potential is conditional, requiring strict medical monitoring and compliance with mandated contraceptive measures.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The official regulatory documentation for Clofazimine details several clinically significant interactions, primarily involving changes in drug concentration or additive effects on the heart.

Key Documented Interaction Types

Interaction Type Interacting Medicines Official Regulatory Statement
Additive QT Risk Bedaquiline; Other QT-prolonging medicines May result in additive QT interval prolongation.
Altered Drug Levels Dapsone; Rifampicin Increases Dapsone plasma concentrations; Reduces Rifampicin plasma concentrations.
CYP3A4 Inhibition Elinzanetant; Mavacamten Increases plasma exposure of these medicines via moderate CYP3A4 inhibition.

No medicinal products are formally listed as contraindicated due to interaction risk in the core FDA prescribing information. The regulatory labeling does not mandate specific time-separation windows for any co-administered medicines.

Population-Specific Cautions

Official prescribing information notes that use should be avoided in patients with hepatic dysfunction, and use requires caution in those with severe renal dysfunction. These cautions relate to the potential for altered drug handling and a heightened risk profile, which impacts interaction relevance.

Mechanism of Action

Disrupting Microbial Energy and Generating Oxidative Stress

The primary action of Clofazimine involves its pro-drug interaction with the bacterial enzyme Type 2 NADH-quinone oxidoreductase ( NDH-2). This process inhibits the microbial electron transfer chain and, crucially, triggers repeated redox cycling, resulting in the massive, self-generated release of toxic Reactive Oxygen Species ( ROS). This mechanism creates fatal intracellular oxidative stress, leading to the cellular toxicity and loss of microbial viability.

Auxiliary Modulation of Host Inflammatory Pathways

Clofazimine exerts a second, independent action by engaging key components of the human immune system. This involves acting as an antagonist of the Kv1.3 ion channel on T-lymphocytes, which reduces their activation and proliferation. Furthermore, the molecule accumulates in macrophages, stimulating the upregulation and release of the anti-inflammatory mediator Interleukin-1 Receptor Antagonist ( IL1RA). This dual immunomodulatory effect produces a systemic physiological consequence that modulates the activity of the host's sustained immune response.

Mechanistic Constraints and Delayed Activity

The complete physiological effect of Clofazimine is constrained by factors that influence its tissue availability. The bactericidal activity is inherently delayed in vivo because it requires significant accumulation of the highly lipophilic molecule within tissues and immune cells to reach concentrations necessary for NDH-2 inhibition and ROS generation. The drug's access to its targets can be functionally limited by the MmpL5 efflux pump, a microbial mechanism that transports the compound out of the cell.

Dosage and Administration Information

Clofazimine is standardized for oral administration using soft gel capsules. The medication is swallowed whole without being crushed or chewed, and it is typically administered with food or milk to aid in absorption.

The medicine is integrated into combination therapy regimens, with specific dosing patterns depending on the clinical scenario. For the management of leprosy, the regimen typically requires a long-term dose ranging from 50 mg to 100 mg once daily. This pattern is maintained as part of a sustained treatment protocol, which may span several years, continuing until bacterial inactivity is confirmed.

A distinct dosing pattern is utilized for the short-term control of severe inflammatory reactions, such as Erythema Nodosum Leprosum (ENL). In this context, the dosage is initially higher, ranging from 100 mg to 300 mg daily, often administered in divided doses. Once the acute inflammation is brought under control, the protocol involves gradually reducing or tapering the dose to 100 mg daily or less for maintenance.

Regarding population-specific use, there is no established dosing guidance for pediatric patients, nor are there explicit numerical adjustments for dose modification in cases of renal or hepatic impairment. This standardization of high-level dosage principles governs the drug's application within formal multi-drug protocols.

Recent Clinical Evidence

Evidence for use in Leprosy (Core Antimicrobial Therapy)

Research is long-standing, derived from historical controlled clinical trials and large programmatic observational studies. These studies evaluated its role in supporting pathogen clearance and monitoring long-term disease recurrence, with outcomes focusing on cure rates. The clinical evaluation is categorized as High based on its long-standing history of inclusion in established protocols, yet the methodology of some earlier trials is associated with a high risk of bias.

Evidence for use in Erythema Nodosum Leprosum (ENL)

Clofazimine was studied for its properties in ENL, a condition marked by heightened symptoms. Research included Randomized Controlled Trials (RCTs) and systematic reviews applied in contexts of fluctuating symptoms. Researchers examined outcomes related to physical discomfort and recurrence rates. Evidence quality varies across studies, and certainty remains low due to modest sample sizes and methodological inconsistencies.

Evidence for use in Drug-Resistant Tuberculosis

Clofazimine was evaluated in combination regimens for MDR-TB. The evidence base is largely derived from systematic reviews and meta-analyses of observational cohort studies. Research examined treatment outcome classification (cure or completion) and sputum culture conversion rates. Evidence is limited by the reliance on observational data; the specific dosage and duration protocols require further confirmation from ongoing research.

Investigational Research in Other Mycobacterial Infections

Research is ongoing to explore the potential role of Clofazimine in treating non-tuberculous mycobacterial (NTM) diseases (e.g., MAC) via modern Phase 2 and Phase 3 Randomized, placebo-controlled clinical trials. Primary endpoints focus on microbiological clearance and patient-reported outcomes describing perceived discomfort. The evidence is still emerging, and the specific role of the drug is not yet fully defined or incorporated into standard guidelines.

Long-Term Studies and Durability of Response

Research has explored the rate of recurrence following Clofazimine-containing regimens, particularly for leprosy. Low reported relapse rates were described over years of patient follow-up. However, for both core uses, follow-up durations were limited in certain study types, and overall there is limited information for long-term outcomes sufficient to draw broad conclusions.

Evidence in Specific Patient Groups

Studies have been conducted that included adults of varying ages, and in some research settings, patients with co-infections such as HIV/TB. However, data related to specific groups remain insufficient, especially to characterize long-term outcomes in pregnant populations or in adults with complex pre-existing conditions.

Key Research Gaps and Uncertainties

Research highlights that evidence quality varies across studies, particularly for ENL where many findings were mixed. Long-term effects are not fully established for outcomes like nerve damage. The optimal dosage and integration into new, shorter regimens for MDR-TB and NTM disease are areas where research is ongoing.

Frequently Asked Questions (FAQ)

Common questions about Clofazimine (FAQ)

Q: Does Clofazimine treat other infections besides leprosy?

Official regulatory documents state that Clofazimine is indicated for the treatment of leprosy. However, due to its properties as an anti-mycobacterial agent, it is also recognized for use in combination regimens for certain forms of drug-resistant tuberculosis.

Q: How quickly does Clofazimine typically start to work?

The full clinical effect of the medicine is generally delayed. Official pharmacokinetic studies indicate the drug has a long half-life, meaning it takes time to accumulate in the body. It may take several months, approximately 1 to 5 months of consistent use, for the concentrations necessary for the clinical effect to be observed.

Q: How long does the skin discoloration from Clofazimine last after treatment is finished?

Skin discoloration is a documented and reversible side effect of this medicine. However, the time required for the color change to fade is highly variable due to the drug's slow clearance from the body. Official patient guidance indicates that the discoloration may take several months or even years to fully resolve after the medication is discontinued.

Q: Does Clofazimine increase sensitivity to sun exposure?

Yes, official safety information indicates that Clofazimine can cause increased sensitivity to sunlight, a condition known as phototoxicity. This means skin may be more susceptible to damage from sun exposure while taking the medication.

Q: Does Clofazimine require special monitoring for heart or liver function?

Due to potential risks related to heart rhythm and impaired liver function, the official product information indicates that close medical surveillance is warranted during treatment. This may include periodic laboratory and cardiac monitoring, particularly for patients with pre-existing conditions.

Q: What are examples of serious drug interactions with Clofazimine?

Regulatory documents list several documented interactions that can affect safety. One example is an additive risk for affecting heart rhythm (known as QT prolongation) when co-administered with other specific medicines, such as Bedaquiline. Severe interactions with certain anti-cancer drugs are also listed in the product information.

Q: Is it generally safe to use Clofazimine during pregnancy?

Official regulatory information states that Clofazimine is not recommended for use during pregnancy because animal studies have shown potential for fetal harm. The regulatory label describes that females of reproductive potential are subject to the restrictions of having a negative pregnancy test and using effective contraception during and for four months after treatment.

Q: Is breastfeeding recommended while taking Clofazimine?

Official regulatory information contains a warning against breastfeeding during treatment. This is because the medicine passes into breast milk and has been associated with a reversible skin discoloration observed in the infant.

Q: What is meant by Clofazimine having a long 'half-life' in the body?

The term 'half-life' describes how long it takes for half of the drug to be eliminated from the body. Clofazimine has a very long terminal half-life, approximately 30 days, as noted in pharmacokinetic summaries. This long duration is why the drug accumulates slowly in body tissues and requires sustained use to achieve its full therapeutic effect.

Q: Why is the drug not commercially available in all regions or countries?

In some regions, the medicine is no longer commercially available through standard pharmacies due to complex factors related to manufacturing and market conditions. In these cases, access is often provided through specialized investigational or public health programs to ensure it remains available for patients who need it.

Q: Does Clofazimine affect blood sugar or cholesterol levels?

Regulatory safety information indicates that a possible adverse reaction includes increased blood glucose (blood sugar) levels. There is no comparable statement in official documents regarding an effect on cholesterol levels.

Q: Can Clofazimine cause discoloration in the eyes or bodily fluids?

Yes, the discoloration side effect extends beyond the skin. Regulatory summaries document that the color change can occur in the conjunctiva and cornea of the eye, as well as in bodily fluids. This includes urine, feces, sweat, saliva, and tears.

Q: Is it common to feel unusually tired or fatigued on Clofazimine?

Regulatory safety documents list both drowsiness and fatigue as possible adverse reactions associated with the medication.

Q: What happens if a patient misses a dose of Clofazimine?

The official patient instructions describe a procedure for missed doses. This guidance typically states that if a dose is missed, it can be taken as soon as it is remembered, unless it is almost time for the next scheduled dose. The instructions caution against taking a double dose to compensate for a missed one.

Q: Is a change in taste a reported side effect of Clofazimine?

Yes, regulatory safety information explicitly lists a change in taste or taste disorder as a reported adverse reaction associated with the use of Clofazimine.

Q: Are there any special warnings about Clofazimine for older adults?

Official information has not identified specific problems that limit the usefulness of the medicine in older adults. However, the regulatory label notes that age-related changes in kidney, liver, or heart function may warrant caution and necessitate adjustment to the therapeutic regimen.

Q: Why is Clofazimine sometimes referred to by the name Lamprene?

Lamprene is the trade or brand name under which the medicine containing the active ingredient clofazimine has historically been marketed. The name Lamprene is still commonly used in patient discussions.

Q: Does the long half-life influence the effects and side effects of the drug?

The medicine's long half-life means it is cleared from the body very slowly. This slow elimination leads to the drug's slow accumulation in body tissues, which directly contributes to the delayed onset of both its therapeutic effects and some of its side effects, such as the long persistence of skin discoloration.

Q: Is Clofazimine a type of chemotherapy drug?

No, Clofazimine is classified as an Antimycobacterial Agent and a Phenazine Antibiotic. It is designed specifically to treat chronic bacterial infections caused by mycobacteria, and it is not classified as a general chemotherapy drug used for treating cancer.

Q: Are there concerns about the quality of life impacts due to the side effects of Clofazimine?

Regulatory safety documents note that the skin discoloration caused by the medicine has been observed to potentially lead to secondary depression and suicidal ideation in some patients.

Q: Does Clofazimine affect the lining of the eyelids?

Yes, regulatory safety information documents that the discoloration side effect can extend to the lining of the eyelids, in addition to other parts of the eye like the cornea and conjunctiva.

Q: What specific type of bacteria does Clofazimine target?

Clofazimine is an anti-mycobacterial agent. Official regulatory and medical sources state that it primarily targets the bacteria Mycobacterium leprae, which is the organism responsible for causing leprosy.

How should Clofazimine be stored and disposed of?

Storage and Disposal of Clofazimine

The official storage requirements for clofazimine are strictly defined to maintain the capsule's stability and effectiveness.

Storage Condition Type Regulatory Requirement
Temperature Controlled Room Temperature, 20 C to 25 C left(68 F -77 F
ight); do not freeze or store above 30 C.
Protection Must be protected from light, moisture, and excessive heat.
Container Rule Keep the capsules in a well-closed, light-resistant container and in the original packaging.
Child Safety Store the medicine out of the reach of children.

Disposal Instructions:

Unused or expired clofazimine must be disposed of according to official guidelines. It should not be flushed down the toilet or poured down a drain. The preferred method for discarding the medicine is utilizing a medicine take-back program or community drug collection center. If a take-back program is unavailable, follow household disposal procedures by mixing the medicine with an undesirable substance before discarding.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Clofazimine found in:

A-Z Index: